Insider Selling: Gilead Sciences, Inc. (GILD) EVP Sells 15,000 Shares of Stock
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the transaction, the executive vice president now owns 64,613 shares in the company, valued at approximately $4,772,962.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $88.80 on Tuesday. The firm has a market cap of $115,970.00, a price-to-earnings ratio of 10.10, a P/E/G ratio of -1.89 and a beta of 1.13. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period last year, the company posted $2.75 earnings per share. equities analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
A number of research analysts recently weighed in on the stock. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a research report on Wednesday, January 3rd. Oppenheimer assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They set a “market perform” rating on the stock. Mizuho increased their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Leerink Swann increased their price objective on shares of Gilead Sciences from $87.00 to $89.00 and gave the company a “market perform” rating in a research report on Thursday, October 5th. Finally, BMO Capital Markets lowered their price objective on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and seventeen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $85.58.
COPYRIGHT VIOLATION WARNING: This piece was reported by Marea Informative and is owned by of Marea Informative. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.mareainformativa.com/2018/01/30/gilead-sciences-inc-gild-evp-sells-1108050-00-in-stock-updated-updated-updated.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.